{"id":"https://openalex.org/W2590875813","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.8067","title":"Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide.","display_name":"Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2590875813","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.8067","mag":"2590875813"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.8067","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.8067","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.8067","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075234719","display_name":"Joe Mikhael","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Mikhael","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066940168","display_name":"S. Vincent Rajkumar","orcid":"https://orcid.org/0000-0002-5862-1833","observed_orcids":["https://orcid.org/0000-0002-5862-1833"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Rajkumar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091287816","display_name":"Vivek Roy","orcid":"https://orcid.org/0000-0002-5950-4620","observed_orcids":["https://orcid.org/0000-0002-5950-4620"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Roy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112254232","display_name":"Susan R. Hayman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. R. Hayman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003015868","display_name":"Rafa\u00ebl Fonseca","orcid":"https://orcid.org/0000-0002-5938-3769","observed_orcids":["https://orcid.org/0000-0002-5938-3769"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Fonseca","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111773471","display_name":"Kristen Detweiler Short","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Detweiler Short","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044733637","display_name":"Betsy R LaPlant","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. LaPlant","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034132697","display_name":"K. M. Laumann","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. M. Laumann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000308170","display_name":"Angela A. Dispenzieri","orcid":"https://orcid.org/0000-0001-8780-9512","observed_orcids":["https://orcid.org/0000-0001-8780-9512"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Dispenzieri","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5076611748","display_name":"Martha Q. Lacy","orcid":"https://orcid.org/0000-0003-1193-1559","observed_orcids":["https://orcid.org/0000-0003-1193-1559"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Lacy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"8067","last_page":"8067"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pomalidomide","display_name":"pomalidomide","score":0.9539999961853027},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9139999747276306},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9739999771118164},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.878000020980835},{"id":"https://openalex.org/keywords/lenalidomide-refractory-disease","display_name":"lenalidomide-refractory disease","score":0.9520000219345093},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.8759999871253967},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.4189999997615814},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.48500001430511475},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8149999976158142},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5210000276565552},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.656000018119812},{"id":"https://openalex.org/keywords/neuropathy","display_name":"neuropathy","score":0.8130000233650208},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.7139999866485596},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.4230000078678131},{"id":"https://openalex.org/keywords/thrombosis","display_name":"thrombosis","score":0.546999990940094},{"id":"https://openalex.org/keywords/deep-vein-thrombosis-prevention","display_name":"deep vein thrombosis prevention","score":0.6119999885559082}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.951799213886261},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.8664588928222656},{"id":"https://openalex.org/C2778524551","wikidata":"https://www.wikidata.org/wiki/Q7227206","display_name":"Pomalidomide","level":4,"score":0.826214075088501},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.7184072732925415},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.650749683380127},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5896143913269043},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.5476795434951782},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5239934325218201},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.4876667261123657},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.46598830819129944},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.43758338689804077},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3980126678943634},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.8067","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.8067","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.8067","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8299999833106995}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1522669222","https://openalex.org/W2171410315","https://openalex.org/W4289835730","https://openalex.org/W2034770517","https://openalex.org/W1974135782","https://openalex.org/W2022036807","https://openalex.org/W3213147857","https://openalex.org/W4292578691","https://openalex.org/W2024305952","https://openalex.org/W2058009067"],"abstract_inverted_index":{"8067":[0],"Background:":[1],"Pomalidomide":[2],"(CC4047":[3],"or":[4,137,254],"Pom)":[5],"is":[6,323,340],"the":[7,61,76],"newest":[8],"oral":[9,114],"immunomodulatory":[10],"agent.":[11],"It":[12],"yields":[13],"less":[14,20],"neuropathy":[15,247],"than":[16,22],"thalidomide":[17],"(thal)":[18],"and":[19,39,125,154,197,231,239,289,311,325,351],"myelosuppression":[21],"lenalidomide":[23],"(len).":[24],"Pom/dex":[25,322,359],"has":[26,53,64],"demonstrated":[27],"response":[28,296,339],"rates":[29],"(>PR)":[30,267],"of":[31,97,229,274],"63%":[32],"in":[33,41,85,227,249,263,270,329,342,360],"relapsed":[34,144],"MM":[35,43,145],"(Lacy,":[36,44],"JCO":[37],"2009)":[38],"32%":[40],"len-refractory":[42],"Leukemia":[45],"2010)":[46],"using":[47,75],"a":[48,71,302],"2mg/day":[49],"dose.":[50],"The":[51],"MTD":[52],"been":[54,67,334],"determined":[55],"to":[56,81,162,207,295],"be":[57],"4":[58],"mg/day":[59],"but":[60],"optimal":[62],"dose":[63,261],"not":[65],"yet":[66],"defined.":[68],"We":[69],"report":[70],"phase":[72,318],"II":[73,319],"trial":[74],"Pom":[77,102],"4mg":[78,103],"with":[79,87,113,132,143,336,348],"dex":[80,115],"study":[82,354],"its":[83],"efficacy":[84],"patients":[86,128,142,170,182,230,259,272,330,361],"prior":[88,98,184],"len.":[89,337],"Methods:":[90],"Patients":[91],"must":[92],"have":[93,332],"had":[94,171,188],"1-3":[95],"lines":[96],"therapy":[99],"(including":[100],"len).":[101],"daily":[104,119,136],"was":[105,150,164,297],"given":[106,116],"orally":[107],"on":[108,120],"days":[109,121],"1\u201328":[110],"(28-day":[111],"cycle)":[112],"40":[117,155],"mg":[118,135],"1,":[122],"8,":[123],"15":[124],"22.":[126],"All":[127],"received":[129,183],"DVT":[130],"prophylaxis":[131],"aspirin":[133],"325":[134],"therapeutic":[138,356],"anticoagulation.":[139],"Results:":[140],"61":[141],"were":[146,156,268,278],"enrolled.":[147],"Median":[148,158,293],"age":[149],"65":[151],"years":[152],"(32-82),":[153],"male.":[157],"time":[159,294],"from":[160],"diagnosis":[161],"enrollment":[163],"37":[165],"months":[166,299],"(1-84).":[167],"Fifteen":[168],"(25%)":[169],"high":[172],"risk":[173],"disease":[174],"as":[175],"defined":[176],"by":[177],"mSMART":[178],"(mSMART.org).":[179],"Sixty":[180],"(98%)":[181],"len,":[185],"29":[186],"(47%)":[187],"bortezomib,":[189],"13":[190],"(21%)":[191],"thal,":[192],"47":[193],"(77%)":[194],"auto":[195],"transplant":[196],"3":[198,223,253],"(5%)":[199],"allo":[200],"transplant.":[201,352],"Toxicities":[202],"at":[203],"least":[204],"possibly":[205],"attributed":[206],"drug":[208],"included":[209,232],"grade":[210,214,218,243,252],"3/4":[211,215,219],"anemia":[212],"(7/0%),":[213],"leukopenia":[216],"(27/2%),":[217],"thrombocytopenia":[220],"(3/2%).":[221],"Grade":[222,245],"non-hematologic":[224],"toxicities":[225],"occurred":[226,248],"18%":[228],"fatigue":[233],"5%,":[234,236],"thrombosis":[235],"hyperglycemia":[237],"5%":[238,241],"pneumonia":[240],"(no":[242,251],"4).":[244,255],"1/2":[246],"18/8%,":[250],"Twenty":[256],"three":[257],"(38%)":[258],"required":[260],"reductions":[262],"dex.":[264],"Confirmed":[265],"responses":[266],"seen":[269,341],"21":[271],"(35%),":[273],"which":[275],"7":[276],"(12%)":[277],"VGPR,":[279],"14":[280],"(23%)":[281],"PR,":[282],"8":[283],"(13%)":[284],"MR,":[285],"25":[286],"(42%)":[287],"SD":[288],"6":[290],"(10%)":[291],"PD.":[292],"1.1":[298],"(0.8-2.8).":[300],"With":[301],"median":[303],"follow-up":[304],"4.1":[305],"months,":[306],"67%":[307],"remain":[308,313],"progression":[309],"free,":[310],"97%":[312],"alive.":[314],"Conclusions:":[315],"This":[316,353],"large":[317],"demonstrates":[320],"that":[321],"active":[324],"very":[326],"well":[327],"tolerated":[328],"who":[331],"already":[333],"treated":[335],"Objective":[338],"48%":[343],"despite":[344],"being":[345],"heavily":[346],"pre-treated":[347],"IMiDs,":[349],"bortezomib":[350],"reconfirms":[355],"benefit":[357],"for":[358],"relapsing":[362],"after":[363],"other":[364],"novel":[365],"therapies.":[366]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}